![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Heavily Funded Biosplice Dumps Its Hair Loss Treatment
Heavily Funded Biosplice Dumps Its Hair Loss Treatment
February 9, 2022
Heavily funded but small-in-size biotech Biosplice has scrapped dalosirvat, its treatment for hair loss in men, which was in late-stage development.
The company also laid off about 25 percent of its workforce as of Feb. 8, including 41 people from its clinical operations team.
Formerly known as Samumed, Biosplice raised a whopping $438 million in 2018 (some of that from Ikea’s venture arm) and another $120 million in April 2021. Its research has been focused on arthritis, hair loss and cancer.
Upcoming Events
-
21Oct